Loading...
The NNRTI etravirine recently joined the first integrase inhibitor, raltegravir, and the first CCR5 antagonist, maraviroc, as one of three new antiretrovirals licensed by the FDA within the last 12 months. Given the impressive short-term efficacy of these drugs among treatment-experienced patients in industry-sponsored trials, many of us were eager to see the data on prolonged therapy from these studies. At the 15th Retrovirus Conference, researchers presented convincing 48-week results for all three drugs, as well as encouraging data about vicriviroc.
In the DUET studies, 61% of patients randomized to etravirine achieved undetectable viral loads (<50 copies/mL) by week 48, compared with 40% of those randomized to placebo (P<0.0001); both gr…